{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:34:50Z","timestamp":1784244890243,"version":"3.55.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"S10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>This joint consensus document of the Austrian Societies of Gastroenterology and Hepatology (\u00d6GGH), Diabetology (\u00d6DG), and Obesity (\u00d6AG) is intended to provide practical guidance for the management of persons with metabolic dysfunction-associated steatotic liver disease (MASLD), including persons with combined metabolic dysfunction and alcohol-related steatotic liver disease (MetALD).<\/jats:p>","DOI":"10.1007\/s00508-025-02617-4","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:25:57Z","timestamp":1760714757000},"page":"307-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1007","volume":"137","author":[{"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Br\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Maria Brix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Datz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Effenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Moritz","family":"Felsenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maieron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas-Matthias","family":"Scherzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Stechemesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian W.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"1","key":"2617_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"M Thursz","year":"2018","unstructured":"Thursz\u00a0M, Gual\u00a0A, Lackner\u00a0C, Mathurin\u00a0P, Moreno\u00a0C, Spahr\u00a0L, et\u00a0al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J\u00a0Hepatol. 2018;69(1):154\u201381.","journal-title":"J Hepatol"},{"issue":"6","key":"2617_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella\u00a0ME, Lazarus\u00a0JV, Ratziu\u00a0V, Francque\u00a0SM, Sanyal\u00a0AJ, Kanwal\u00a0F, et\u00a0al. A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature. J\u00a0Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"Suppl\u00a03","key":"2617_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00508-023-02229-w","volume":"135","author":"M Mandorfer","year":"2023","unstructured":"Mandorfer\u00a0M, Aigner\u00a0E, Cejna\u00a0M, Ferlitsch\u00a0A, Datz\u00a0C, Gr\u00e4ter\u00a0T, et\u00a0al. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV). Wien Klin Wochenschr. 2023;135(Suppl\u00a03):493\u2013523.","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"2617_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis\u00a0R, Bosch\u00a0J, Garcia-Tsao\u00a0G, Reiberger\u00a0T, Ripoll\u00a0C. Baveno VII\u2014Renewing consensus in portal hypertension. J\u00a0Hepatol. 2022;76(4):959\u201374.","journal-title":"J Hepatol"},{"issue":"7650","key":"2617_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt\u00a0GH, Oxman\u00a0AD, Vist\u00a0GE, Kunz\u00a0R, Falck-Ytter\u00a0Y, Alonso-Coello\u00a0P, et\u00a0al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"3","key":"2617_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"-","year":"2024","unstructured":"-. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J\u00a0Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"5","key":"2617_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella\u00a0ME, Neuschwander-Tetri\u00a0BA, Siddiqui\u00a0MS, Abdelmalek\u00a0MF, Caldwell\u00a0S, Barb\u00a0D, et\u00a0al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"3","key":"2617_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"-","year":"2021","unstructured":"-. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J\u00a0Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"2","key":"2617_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","volume":"20","author":"DE Kleiner","year":"2016","unstructured":"Kleiner\u00a0DE, Makhlouf\u00a0HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis. 2016;20(2):293\u2013312.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"2617_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling\u00a0RK, Duarte-Rojo\u00a0A, Patel\u00a0K, Asrani\u00a0SK, Alsawas\u00a0M, Dranoff\u00a0JA, et\u00a0al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(2):672\u2013724.","journal-title":"Hepatology"},{"issue":"4","key":"2617_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","volume":"54","author":"EA Tsochatzis","year":"2011","unstructured":"Tsochatzis\u00a0EA, Gurusamy\u00a0KS, Ntaoula\u00a0S, Cholongitas\u00a0E, Davidson\u00a0BR, Burroughs\u00a0AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a\u00a0meta-analysis of diagnostic accuracy. J\u00a0Hepatol. 2011;54(4):650\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"2617_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab\u00a0JP, D\u00edaz\u00a0LA, Rehm\u00a0J, Im\u00a0G, Arrese\u00a0M, Kamath\u00a0PS, et\u00a0al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J\u00a0Hepatol. 2025;82(4):744\u201356.","journal-title":"J Hepatol"},{"key":"2617_CR13","doi-asserted-by":"crossref","unstructured":"Diaz\u00a0LA, Ajmera\u00a0V, Arab\u00a0JP, Huang\u00a0DQ, Hsu\u00a0C, Lee\u00a0BP, et\u00a0al. An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2025. In press.","DOI":"10.1016\/j.cgh.2025.02.017"},{"issue":"24","key":"2617_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin\u00a0M, Rinella\u00a0ME, Chalasani\u00a0NP, Neff\u00a0GW, Lucas\u00a0KJ, Rodriguez\u00a0ME, et\u00a0al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N\u00a0Engl J Med. 2025;392(24):2413\u201324.","journal-title":"N Engl J Med"},{"issue":"3","key":"2617_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino\u00a0F, Cummings\u00a0DE, Eckel\u00a0RH, Cohen\u00a0RV, Wilding\u00a0JPH, Brown\u00a0WA, et\u00a0al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2617_CR16","doi-asserted-by":"crossref","unstructured":"Semmler\u00a0G, Th\u00f6ne\u00a0P, Embacher\u00a0J, Hruska\u00a0P, Simonis\u00a0L, Stopfer\u00a0K, et\u00a0al. Prevalence of fibrosis and applicability of lab-based non-invasive tests from primary to tertiary care. Clin Gastroenterol Hepatol. 2025. In press.","DOI":"10.1016\/j.cgh.2025.09.008"},{"key":"2617_CR17","doi-asserted-by":"crossref","unstructured":"Ho\u00a0GJK, Tan\u00a0FXN, Sasikumar\u00a0NA, Tham\u00a0EKJ, Ko\u00a0D, Kim\u00a0DH, et\u00a0al. High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysis. Clin Gastroenterol Hepatol. 2025. In press.","DOI":"10.1016\/j.cgh.2025.02.006"},{"key":"2617_CR18","doi-asserted-by":"publisher","first-page":"1244405","DOI":"10.3389\/fendo.2023.1244405","volume":"14","author":"G Semmler","year":"2023","unstructured":"Semmler\u00a0G, Balcar\u00a0L, Wernly\u00a0S, V\u00f6lkerer\u00a0A, Semmler\u00a0L, Hauptmann\u00a0L, et\u00a0al. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Front Endocrinol. 2023;14:1244405.","journal-title":"Front Endocrinol"},{"key":"2617_CR19","unstructured":"Younossi\u00a0ZM, Zelber-Sagi\u00a0S, Lazarus\u00a0JV, Wong\u00a0VW, Yilmaz\u00a0Y, Duseja\u00a0A, et\u00a0al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025. In press."},{"issue":"2","key":"2617_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard\u00a0M, Lindvig\u00a0KP, Thorhauge\u00a0KH, Andersen\u00a0P, Hansen\u00a0JK, Kastrup\u00a0N, et\u00a0al. Using the ELF test, FIB\u20114 and NAFLD fibrosis score to screen the population for liver disease. J\u00a0Hepatol. 2023;79(2):277\u201386.","journal-title":"J Hepatol"},{"issue":"8","key":"2617_CR21","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/liv.15323","volume":"42","author":"JL Calleja","year":"2022","unstructured":"Calleja\u00a0JL, Rivera-Esteban\u00a0J, Aller\u00a0R, Hern\u00e1ndez-Conde\u00a0M, Abad\u00a0J, Peric\u00e0s\u00a0JM, et\u00a0al. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. Liver Int. 2022;42(8):1783\u201392.","journal-title":"Liver Int"},{"issue":"1","key":"2617_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.27981","volume":"63","author":"EM Koehler","year":"2016","unstructured":"Koehler\u00a0EM, Plompen\u00a0EP, Schouten\u00a0JN, Hansen\u00a0BE, Darwish\u00a0MS, Taimr\u00a0P, et\u00a0al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a\u00a0general population: The Rotterdam study. Hepatology. 2016;63(1):138\u201347.","journal-title":"Hepatology"},{"issue":"1","key":"2617_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek\u00a0J, Chan\u00a0KE, Wong\u00a0ZY, Tan\u00a0C, Tan\u00a0B, Lim\u00a0WH, et\u00a0al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a\u00a0systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2617_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2468-1253(24)00313-3","volume":"10","author":"A Lindfors","year":"2025","unstructured":"Lindfors\u00a0A, Strandberg\u00a0R, Hagstr\u00f6m\u00a0H. Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type\u00a02 diabetes: a\u00a0cross-sectional study. Lancet Gastroenterol Hepatol. 2025;10(2):125\u201337.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2617_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor\u00a0RS, Taylor\u00a0RJ, Bayliss\u00a0S, Hagstr\u00f6m\u00a0H, Nasr\u00a0P, Schattenberg\u00a0JM, et\u00a0al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A\u00a0Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611\u20131625.e1.","journal-title":"Gastroenterology"},{"issue":"4","key":"2617_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng\u00a0CH, Lim\u00a0WH, Lim\u00a0HGE, Tan\u00a0HDJ, Syn\u00a0N, Muthiah\u00a0MD, et\u00a0al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A\u00a0Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931\u2013939.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2617_CR27","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai\u00a0PS, Singh\u00a0S, Patel\u00a0J, Soni\u00a0M, Prokop\u00a0LJ, Younossi\u00a0Z, et\u00a0al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u201365.","journal-title":"Hepatology"},{"issue":"8","key":"2617_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali\u00a0Y, Lee\u00a0J, Boursier\u00a0J, Petta\u00a0S, Wonders\u00a0K, Tiniakos\u00a0D, et\u00a0al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a\u00a0comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714\u201325.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2617_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m\u00a0H, Nasr\u00a0P, Ekstedt\u00a0M, Hammar\u00a0U, St\u00e5l\u00a0P, Hultcrantz\u00a0R, et\u00a0al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J\u00a0Hepatol. 2017;67(6):1265\u201373.","journal-title":"J Hepatol"},{"issue":"2","key":"2617_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo\u00a0P, Kleiner\u00a0DE, Dam-Larsen\u00a0S, Adams\u00a0LA, Bjornsson\u00a0ES, Charatcharoenwitthaya\u00a0P, et\u00a0al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389\u201397.e10.","journal-title":"Gastroenterology"},{"key":"2617_CR31","doi-asserted-by":"publisher","first-page":"c1240","DOI":"10.1136\/bmj.c1240","volume":"340","author":"CL Hart","year":"2010","unstructured":"Hart\u00a0CL, Morrison\u00a0DS, Batty\u00a0GD, Mitchell\u00a0RJ, Smith\u00a0DG. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Bmj (clinical Res Ed). 2010;340:c1240.","journal-title":"Bmj (clinical Res Ed)"},{"issue":"6","key":"2617_CR32","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/hep.29631","volume":"67","author":"F \u00c5berg","year":"2018","unstructured":"\u00c5berg\u00a0F, Helenius-Hietala\u00a0J, Puukka\u00a0P, F\u00e4rkkil\u00e4\u00a0M, Jula\u00a0A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67(6):2141\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"2617_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/acer.14271","volume":"44","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg\u00a0F, F\u00e4rkkil\u00e4\u00a0M, M\u00e4nnist\u00f6\u00a0V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A\u00a0Critical Review of Epidemiological Studies. Alcohol Clin Exp Res. 2020;44(2):384\u2013403.","journal-title":"Alcohol Clin Exp Res"},{"issue":"10152","key":"2617_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"MG Griswold","year":"2018","unstructured":"Griswold\u00a0MG, Fullman\u00a0N, Hawley\u00a0C, Arian\u00a0N, Zimsen\u00a0SRM, Tymeson\u00a0HD, et\u00a0al. Alcohol use and burden for 195 countries and territories, 1990&#x2013;2016: a\u00a0systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015\u201335.","journal-title":"Lancet"},{"issue":"6","key":"2617_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling\u00a0RK, Lissen\u00a0E, Clumeck\u00a0N, Sola\u00a0R, Correa\u00a0MC, Montaner\u00a0J, et\u00a0al. Development of a\u00a0simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"Suppl\u00a03","key":"2617_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00508-017-1262-3","volume":"129","author":"T Reiberger","year":"2017","unstructured":"Reiberger\u00a0T, P\u00fcsp\u00f6k\u00a0A, Schoder\u00a0M, Baumann-Durchschein\u00a0F, Bucsics\u00a0T, Datz\u00a0C, et\u00a0al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017;129(Suppl\u00a03):135\u201358.","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"2617_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","volume":"50","author":"G Ferraioli","year":"2024","unstructured":"Ferraioli\u00a0G, Barr\u00a0RG, Berzigotti\u00a0A, Sporea\u00a0I, Wong\u00a0VW, Reiberger\u00a0T, et\u00a0al. WFUMB Guideline\/Guidance on Liver Multiparametric Ultrasound: Part\u00a01. Update to 2018 Guidelines on Liver Ultrasound Elastography. Ultrasound Med Biol. 2024;50(8):1071\u201387.","journal-title":"Ultrasound Med Biol"},{"issue":"7","key":"2617_CR38","first-page":"1057","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi\u00a0K, Abdelmalek\u00a0MF, Apovian\u00a0CM, Balapattabi\u00a0K, Bannuru\u00a0RR, Barb\u00a0D, et\u00a0al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A\u00a0Consens Rep Am Diabetes Assoc Diabetes Care. 2025;48(7):1057\u201382.","journal-title":"A Consens Rep Am Diabetes Assoc Diabetes Care"},{"key":"2617_CR39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(25)00298-3","volume":"82","author":"M Pavlides","year":"2025","unstructured":"Pavlides\u00a0M, Vali\u00a0Y, Mozes\u00a0F, Wonders\u00a0K, Akthar\u00a0S, Aithal\u00a0G, et\u00a0al. GS-001 Diagnostic performance of imaging and serum based MASLD biomarkers: robust validation in the prospective LITMUS imaging study. J\u00a0Hepatol. 2025;82:S1\u2013S2.","journal-title":"J Hepatol"},{"issue":"3","key":"2617_CR40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/HEP.0000000000000844","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling\u00a0RK, Asrani\u00a0SK, Levine\u00a0D, Duarte-Rojo\u00a0A, Patel\u00a0K, Fiel\u00a0MI, et\u00a0al. AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension. Hepatology. 2025;81(3):1060\u201385.","journal-title":"Hepatology"},{"issue":"4","key":"2617_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons\u00a0M, Augustin\u00a0S, Scheiner\u00a0B, Guillaume\u00a0M, Rosselli\u00a0M, Rodrigues\u00a0SG, et\u00a0al. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol. 2021;116(4):723\u201332.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2617_CR42","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","volume":"9","author":"M Jachs","year":"2024","unstructured":"Jachs\u00a0M, Odriozola\u00a0A, Turon\u00a0F, Moga\u00a0L, T\u00e9llez\u00a0L, Fischer\u00a0P, et\u00a0al. Spleen stiffness measurement by vibration-controlled transient elastography at 100\u202fHz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a\u00a0modelling study. Lancet Gastroenterol Hepatol. 2024;9(12):1111\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2617_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez\u00a0E, Martinez-Perez\u00a0Y, Calzadilla-Bertot\u00a0L, Torres-Gonzalez\u00a0A, Gra-Oramas\u00a0B, Gonzalez-Fabian\u00a0L, et\u00a0al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367\u2013378.e5.","journal-title":"Gastroenterology"},{"issue":"6","key":"2617_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","volume":"69","author":"VW Wong","year":"2018","unstructured":"Wong\u00a0VW, Wong\u00a0GL, Chan\u00a0RS, Shu\u00a0SS, Cheung\u00a0BH, Li\u00a0LS, et\u00a0al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J\u00a0Hepatol. 2018;69(6):1349\u201356.","journal-title":"J Hepatol"},{"issue":"6","key":"2617_CR45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jgh.15363","volume":"36","author":"S Hassani Zadeh","year":"2021","unstructured":"Hassani Zadeh\u00a0S, Mansoori\u00a0A, Hosseinzadeh\u00a0M. Relationship between dietary patterns and non-alcoholic fatty liver disease: A\u00a0systematic review and meta-analysis. J\u00a0Gastroenterol Hepatol. 2021;36(6):1470\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"2617_CR46","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.cgh.2021.11.001","volume":"20","author":"WY Park","year":"2022","unstructured":"Park\u00a0WY, Yiannakou\u00a0I, Petersen\u00a0JM, Hoffmann\u00a0U, Ma\u00a0J, Long\u00a0MT. Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study. Clin Gastroenterol Hepatol. 2022;20(11):2524\u20132532.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2617_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","volume":"113","author":"N Simons","year":"2021","unstructured":"Simons\u00a0N, Veeraiah\u00a0P, Simons\u00a0P, Schaper\u00a0NC, Kooi\u00a0ME, Schrauwen-Hinderling\u00a0VB, et\u00a0al. Effects of fructose restriction on liver steatosis (FRUITLESS); a\u00a0double-blind randomized controlled trial. Am J Clin Nutr. 2021;113(2):391\u2013400.","journal-title":"Am J Clin Nutr"},{"key":"2617_CR48","doi-asserted-by":"crossref","unstructured":"Lee D, Chiavaroli L, Ayoub-Charette S, Khan TA, Zurbau A, Au-Yeung F, et\u00a0al. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A\u00a0Systematic Review and Meta-Analysis of Controlled Trials. Nutrients. 2022;14(14).","DOI":"10.3390\/nu14142846"},{"issue":"1","key":"2617_CR49","doi-asserted-by":"publisher","first-page":"e16220","DOI":"10.1111\/liv.16220","volume":"45","author":"I Alabdul Razzak","year":"2025","unstructured":"Alabdul Razzak\u00a0I, Fares\u00a0A, Stine\u00a0JG, Trivedi\u00a0HD. The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective. Liver Int. 2025;45(1):e16220.","journal-title":"Liver Int"},{"issue":"9","key":"2617_CR50","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/liv.15947","volume":"44","author":"DJ Cuthbertson","year":"2024","unstructured":"Cuthbertson\u00a0DJ, Keating\u00a0SE, Pugh\u00a0CJA, Owen\u00a0PJ, Kemp\u00a0GJ, Umpleby\u00a0M, et\u00a0al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver Int. 2024;44(9):2368\u201381.","journal-title":"Liver Int"},{"issue":"1","key":"2617_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","volume":"57","author":"SE Keating","year":"2012","unstructured":"Keating\u00a0SE, Hackett\u00a0DA, George\u00a0J, Johnson\u00a0NA. Exercise and non-alcoholic fatty liver disease: a\u00a0systematic review and meta-analysis. J\u00a0Hepatol. 2012;57(1):157\u201366.","journal-title":"J Hepatol"},{"issue":"1","key":"2617_CR52","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","volume":"14","author":"Y Xue","year":"2024","unstructured":"Xue\u00a0Y, Peng\u00a0Y, Zhang\u00a0L, Ba\u00a0Y, Jin\u00a0G, Liu\u00a0G. Effect of different exercise modalities on nonalcoholic fatty liver disease: a\u00a0systematic review and network meta-analysis. Sci Rep. 2024;14(1):6212.","journal-title":"Sci Rep"},{"issue":"9\u201310","key":"2617_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00508-023-02314-0","volume":"136","author":"M Li","year":"2024","unstructured":"Li\u00a0M. Association of physical activity with MAFLD\/MASLD and LF among adults in NHANES. Wien Klin Wochenschr. 2024;136(9\u201310):258\u201366.","journal-title":"Wien Klin Wochenschr"},{"key":"2617_CR54","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.aohep.2020.08.071","volume":"20","author":"U Hayat","year":"2021","unstructured":"Hayat\u00a0U, Siddiqui\u00a0AA, Okut\u00a0H, Afroz\u00a0S, Tasleem\u00a0S, Haris\u00a0A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A\u00a0meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254.","journal-title":"Ann Hepatol"},{"issue":"9","key":"2617_CR55","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.cgh.2021.09.042","volume":"20","author":"S Niezen","year":"2022","unstructured":"Niezen\u00a0S, Mehta\u00a0M, Jiang\u00a0ZG, Tapper\u00a0EB. Coffee Consumption Is Associated With Lower Liver Stiffness: A\u00a0Nationally Representative Study. Clin Gastroenterol Hepatol. 2022;20(9):2032\u20132040.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2617_CR56","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/MEG.0000000000000776","volume":"29","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha\u00a0K, Thongprayoon\u00a0C, Ungprasert\u00a0P. Coffee consumption and risk of nonalcoholic fatty liver disease: a\u00a0systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8\u2013e12.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"2617_CR57","doi-asserted-by":"publisher","first-page":"e0142457","DOI":"10.1371\/journal.pone.0142457","volume":"10","author":"F Liu","year":"2015","unstructured":"Liu\u00a0F, Wang\u00a0X, Wu\u00a0G, Chen\u00a0L, Hu\u00a0P, Ren\u00a0H, et\u00a0al. Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A\u00a0Meta-Analysis. Plos One. 2015;10(11):e142457.","journal-title":"Plos One"},{"issue":"1","key":"2617_CR58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","volume":"70","author":"-","year":"2019","unstructured":"-. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J\u00a0Hepatol. 2019;70(1):172\u201393.","journal-title":"J Hepatol"},{"issue":"5","key":"2617_CR59","doi-asserted-by":"publisher","first-page":"950","DOI":"10.14309\/ajg.0000000000003379","volume":"120","author":"AK Singal","year":"2025","unstructured":"Singal\u00a0AK, Wong\u00a0RJ, Dasarathy\u00a0S, Abdelmalek\u00a0MF, Neuschwander-Tetri\u00a0BA, Limketkai\u00a0BN, et\u00a0al. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. Am J Gastroenterol. 2025;120(5):950\u201372.","journal-title":"Off J Am Coll Gastroenterol | Acg"},{"issue":"6","key":"2617_CR60","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison\u00a0SA, Bedossa\u00a0P, Guy\u00a0CD, Schattenberg\u00a0JM, Loomba\u00a0R, Taub\u00a0R, et\u00a0al. A\u00a0Phase\u00a03, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N\u00a0Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"21","key":"2617_CR61","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal\u00a0AJ, Newsome\u00a0PN, Kliers\u00a0I, \u00d8stergaard\u00a0LH, Long\u00a0MT, Kj\u00e6r\u00a0MS, et\u00a0al. Phase\u00a03 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N\u00a0Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"15","key":"2617_CR62","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin\u00a0H, Lee\u00a0HW, Yip\u00a0TC\u2011F, Tsochatzis\u00a0E, Petta\u00a0S, Bugianesi\u00a0E, et\u00a0al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331(15):1287-1297.","journal-title":"JAMA"},{"issue":"4","key":"2617_CR63","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","volume":"165","author":"G Semmler","year":"2023","unstructured":"Semmler\u00a0G, Yang\u00a0Z, Fritz\u00a0L, K\u00f6ck\u00a0F, Hofer\u00a0BS, Balcar\u00a0L, et\u00a0al. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease. Gastroenterology. 2023;165(4):1041\u201352.","journal-title":"Gastroenterology"},{"issue":"1","key":"2617_CR64","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen\u00a0VL, Morgan\u00a0TR, Rotman\u00a0Y, Patton\u00a0HM, Cusi\u00a0K, Kanwal\u00a0F, et\u00a0al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312\u201320.","journal-title":"Hepatology"},{"issue":"4","key":"2617_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba\u00a0R, Hartman\u00a0ML, Lawitz\u00a0EJ, Vuppalanchi\u00a0R, Boursier\u00a0J, Bugianesi\u00a0E, et\u00a0al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N\u00a0Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"4","key":"2617_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal\u00a0AJ, Bedossa\u00a0P, Fraessdorf\u00a0M, Neff\u00a0GW, Lawitz\u00a0E, Bugianesi\u00a0E, et\u00a0al. A\u00a0Phase\u00a02 Randomized Trial of Survodutide in MASH and Fibrosis. N\u00a0Engl J Med. 2024;391(4):311\u20139.","journal-title":"N Engl J Med"},{"key":"2617_CR67","volume-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","author":"M Souza","year":"2025","unstructured":"Souza\u00a0M, Al-Sharif\u00a0L, Antunes\u00a0VLJ, Huang\u00a0DQ, Loomba\u00a0R. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Hepatology. 2025. In press."},{"key":"2617_CR68","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin\u00a0J, Huang\u00a0Y, Xu\u00a0B, Gu\u00a0X, Huang\u00a0J, Sun\u00a0J, et\u00a0al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e83735.","journal-title":"BMJ"},{"issue":"3","key":"2617_CR69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/flgastro-2024-102856","volume":"16","author":"SD Isaacs","year":"2025","unstructured":"Isaacs\u00a0SD, Farrelly\u00a0FV, Brennan\u00a0PN. Role of anti-diabetic medications in the management of MASLD. Frontline Gastroenterol. 2025;16(3):239\u201349.","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"2617_CR70","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/dom.13186","volume":"20","author":"L Jensen","year":"2018","unstructured":"Jensen\u00a0L, Kupcova\u00a0V, Arold\u00a0G, Pettersson\u00a0J, Hjerpsted\u00a0JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998\u20131005.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2617_CR71","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","volume":"81","author":"EJ Lawitz","year":"2024","unstructured":"Lawitz\u00a0EJ, Fraessdorf\u00a0M, Neff\u00a0GW, Schattenberg\u00a0JM, Noureddin\u00a0M, Alkhouri\u00a0N, et\u00a0al. Efficacy, tolerability and pharmacokinetics of survodutide, a\u00a0glucagon\/glucagon-like peptide\u20111 receptor dual agonist, in cirrhosis. J\u00a0Hepatol. 2024;81(5):837\u201346.","journal-title":"J Hepatol"},{"issue":"6","key":"2617_CR72","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba\u00a0R, Abdelmalek\u00a0MF, Armstrong\u00a0MJ, Jara\u00a0M, Kj\u00e6r\u00a0MS, Krarup\u00a0N, et\u00a0al. Semaglutide 2\u00b74\u202fmg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a\u00a0randomised, placebo-controlled phase\u00a02\u00a0trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2617_CR73","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","volume":"61","author":"S Urva","year":"2022","unstructured":"Urva\u00a0S, Quinlan\u00a0T, Landry\u00a0J, Ma\u00a0X, Martin\u00a0JA, Benson\u00a0CT. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP\u20111 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022;61(7):1057\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"2617_CR74","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1097\/TP.0000000000005070","volume":"108","author":"HC Gonzalez","year":"2024","unstructured":"Gonzalez\u00a0HC, Myers\u00a0DT, Venkat\u00a0D. Successful Implementation of a\u00a0Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index. Transplantation. 2024;108(11):2233\u20137.","journal-title":"Transplantation"},{"issue":"1","key":"2617_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","volume":"5","author":"E Pose","year":"2020","unstructured":"Pose\u00a0E, Napoleone\u00a0L, Amin\u00a0A, Campion\u00a0D, Jimenez\u00a0C, Piano\u00a0S, et\u00a0al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a02\u00a0trial. Lancet Gastroenterol Hepatol. 2020;5(1):31\u201341.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2617_CR76","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2024.27441","volume":"333","author":"E Pose","year":"2025","unstructured":"Pose\u00a0E, Jim\u00e9nez\u00a0C, Zaccherini\u00a0G, Campion\u00a0D, Piano\u00a0S, Uschner\u00a0FE, et\u00a0al. Simvastatin and Rifaximin in Decompensated Cirrhosis: A\u00a0Randomized Clinical Trial. JAMA. 2025;333(10):864\u201374.","journal-title":"JAMA"},{"key":"2617_CR77","doi-asserted-by":"crossref","unstructured":"Kronborg TM, Schierwagen R, Tro\u0161t K, Gao Q, Moritz T, Bendtsen F, et\u00a0al. Atorvastatin for patients with cirrhosis. A\u00a0randomized, placebo-controlled trial. Hepatol Commun. 2023;7(12).","DOI":"10.1097\/HC9.0000000000000332"},{"issue":"10","key":"2617_CR78","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","volume":"58","author":"SG Simonson","year":"2003","unstructured":"Simonson\u00a0SG, Martin\u00a0PD, Mitchell\u00a0P, Schneck\u00a0DW, Lasseter\u00a0KC, Warwick\u00a0MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol. 2003;58(10):669\u201375.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2617_CR79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11695-023-06913-8","volume":"34","author":"P Salminen","year":"2024","unstructured":"Salminen\u00a0P, Kow\u00a0L, Aminian\u00a0A, Kaplan\u00a0LM, Nimeri\u00a0A, Prager\u00a0G, et\u00a0al. IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management\u2014an International Delphi Study. Oves Surg. 2024;34(1):30\u201342.","journal-title":"Obes Surg"},{"issue":"3","key":"2617_CR80","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41591-024-03480-y","volume":"31","author":"A Aminian","year":"2025","unstructured":"Aminian\u00a0A, Aljabri\u00a0A, Wang\u00a0S, Bena\u00a0J, Allende\u00a0DS, Rosen\u00a0H, et\u00a0al. Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31(3):988\u201395.","journal-title":"Nat Med"},{"key":"2617_CR81","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease. J Hepatol. 2025;83(3):768-89.","DOI":"10.1016\/j.jhep.2025.04.008"},{"issue":"5","key":"2617_CR82","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal\u00a0AJ, Anstee\u00a0QM, Trauner\u00a0M, Lawitz\u00a0EJ, Abdelmalek\u00a0MF, Ding\u00a0D, et\u00a0al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022;75(5):1235\u201346.","journal-title":"Hepatology"},{"issue":"1","key":"2617_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jhep.2024.02.019","volume":"81","author":"KH Thorhauge","year":"2024","unstructured":"Thorhauge\u00a0KH, Semmler\u00a0G, Johansen\u00a0S, Lindvig\u00a0KP, Kj\u00e6rgaard\u00a0M, Hansen\u00a0JK, et\u00a0al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol. 2024;81(1):23-32.","journal-title":"J Hepatol."},{"issue":"4","key":"2617_CR84","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","volume":"81","author":"S Gawrieh","year":"2024","unstructured":"Gawrieh\u00a0S, Vilar-Gomez\u00a0E, Wilson\u00a0LA, Pike\u00a0F, Kleiner\u00a0DE, Neuschwander-Tetri\u00a0BA, et\u00a0al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J\u00a0Hepatol. 2024;81(4):600\u20138.","journal-title":"J Hepatol"},{"issue":"2","key":"2617_CR85","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30418","volume":"70","author":"EM Brunt","year":"2019","unstructured":"Brunt\u00a0EM, Kleiner\u00a0DE, Wilson\u00a0LA, Sanyal\u00a0AJ, Neuschwander-Tetri\u00a0BA. Network ftNSCR. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019;70(2):522\u201331.","journal-title":"Hepatology"},{"issue":"10","key":"2617_CR86","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner\u00a0DE, Brunt\u00a0EM, Wilson\u00a0LA, Behling\u00a0C, Guy\u00a0C, Contos\u00a0M, et\u00a0al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. Jama Netw Open. 2019;2(10):e1912565\u2013e.","journal-title":"Jama Netw Open"},{"issue":"2","key":"2617_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J\u00a0Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"7","key":"2617_CR88","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/liv.15919","volume":"44","author":"H Hegmar","year":"2024","unstructured":"Hegmar\u00a0H, Wester\u00a0A, Aleman\u00a0S, Backman\u00a0J, Degerman\u00a0E, Ekvall\u00a0H, et\u00a0al. Liver stiffness predicts progression to liver-related events in patients with chronic liver disease\u2014A cohort study of 14 414 patients. Liver Int. 2024;44(7):1689\u201399.","journal-title":"Liver Int"},{"key":"2617_CR89","unstructured":"Lai\u00a0JC\u2011T, Yang\u00a0B, Lee\u00a0HW, Lin\u00a0H, Tsochatzis\u00a0EA, Petta\u00a0S, et\u00a0al. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025. In press."},{"key":"2617_CR90","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0168-8278(25)01723-4","volume":"82","author":"J Embacher","year":"2025","unstructured":"Embacher\u00a0J, Semmler\u00a0G, Jachs\u00a0M, Balcar\u00a0L, Th\u00f6ne\u00a0P, Sebesta\u00a0C, et\u00a0al. WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance. J Hepatol;2025;82:S646.","journal-title":"J Hepatol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02617-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:13:10Z","timestamp":1761847990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02617-4"}},"subtitle":["Austrian Society of Gastroenterology and Hepatology (\u00d6GGH), Austrian Society of Diabetology (\u00d6DG), Austrian Society of Obesity (\u00d6AG)"],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":90,"journal-issue":{"issue":"S10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02617-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"25 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article has been revised: The name of the author Daniel Moritz Felsenreich was incorrectly tagged. This has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Mandorfer received grant support from Echosens, served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, AstraZeneca, Echosens, Eli Lilly, Gilead, Ipsen, Takeda, and W. L. Gore & Associates, and received travel support from AbbVie and Gilead. G.\u00a0Semmler received travel support from Amgen. E.\u00a0Aigner served as speaker and\/or advisory board member for Sanofi-Aventis, Gilead, Eli Lilly, Boehringer Ingelheim, Bayer, Falk Pharma, Amicus, Takeda, and Roche and received travel support from Sanofi-Aventis, Gilead, Eli Lilly, Boehringer, Bayer, Falk Pharma, Amicus, Takeda, and Roche. A.\u00a0Br\u00e4uer served as speaker and\/or consultant and\/or advisory board member for Eli Lilly and Novo Nordisk and received travel support from Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. J.\u00a0Maria Brix served as speaker and\/or consultant and\/or advisory board member for AstraZeneca, Dexcom, Boehringer Ingelheim, Eli Lilly, Medtronic, and Novo Nordisk. M.\u00a0Effenberger served as a\u00a0speaker and\/or consultant and\/or advisory board member for Ipsen and received travel support from Ipsen. A.\u00a0Maieron served as speaker and\/or consultant and\/or advisory board member for Boehringer Ingelheim, Eli Lilly, MSD, and Madrigal. B.\u00a0Ludvik received grant support from Boehringer-Ingelheim, Novo Nordisk, Madrigal, Eli Lilly, and Amgen and served as a\u00a0speaker\/advisor for AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. M.\u00a0Peck-Radosavljevic served as speaker and\/or advisory board member for AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Eisai, Falk, Gilead, Ipsen, Intercept-Advanz, Merz, MSD, Roche, Sanofi, Shionogi, and Sobi. L.\u00a0Stechemesser served as speaker and\/or consultant and\/or advisory board member for Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. M.\u00a0Trauner received grant support from Albireo, Alnylam, Cymabay, Falk Pharma, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx; honoraria for consulting from AbbVie, Albireo, Agomab, Alfasigma, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk Pharma, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Janssen, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, ProQR Therapeutics, Siemens, and Shire; speaker fees from Albireo, Boehringer Ingelheim, BMS, Falk Foundation, Gilead, Ipsen, Intercept, Mirum, MSD, and Madrigal as well as travel support from AbbVie, Falk Foundation, Gilead, Jannsen, Intercept, and Ipsen. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as employee) filed by the Medical University of Graz. H.\u00a0Hofer served as a\u00a0speaker and\/or advisory board member for AbbVie, Falk Pharma, Gilead, Ipsen, Eli Lilly, Boehringer Ingelheim, and Madrigal, and received travel support from Abbvie, Falk Pharma, Gilead, Ipsen, Eli Lilly, Boehringer Ingelheim, and Madrigal. F.W.\u00a0Kiefer served as speaker and\/or consultant and\/or advisory board member for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, and Sanofi Aventis. P.\u00a0Fasching served as speaker and\/or consultant and\/or advisory board member for Boehringer Ingelheim, Eli Lilly, and Novo Nordisk and received travel support from Boehringer Ingelheim and Novo Nordisk. M.\u00a0Roden received grant support for investigator-initiated research from Boehringer Ingelheim, Novo Nordisk, and Sanofi-Aventis to the German Diabetes Center (DDZ) and served as a\u00a0speaker and\/or consultant and\/or advisory board member for AstraZeneca, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk, Pfizer, Synlab, and Target RWE. M.\u00a0Clodi, C.\u00a0Datz, D.\u00a0Moritz Felsenreich, C.\u00a0Ress, T.-M.\u00a0Scherzer, H.\u00a0Sourij, M.\u00a0Wagner, and H.\u00a0Tilg have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}